Location Directory

Clinical trials in Miami, Florida

This page shows live ClinicalTrials.gov search results for Miami, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

12548

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Breast Cancer
Interventions: Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression; Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 3,960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 1240
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 813 more

Conditions: Sleep Apnea, Obstructive, Obesity, Overweight
Interventions: Eloralintide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 23
States / cities: Cullman, Alabama • Long Beach, California • Los Alamitos, California + 19 more

Conditions: Chronic Kidney Diseases
Interventions: Placebo, KBP-5074; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 65
States / cities: Foley, Alabama • Huntsville, Alabama • Mesa, Arizona + 47 more

Conditions: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions: LY3650150, Placebo, Standard therapy for INCS; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 41
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 32 more

Conditions: Ulcerative Colitis, Obesity or Overweight
Interventions: Mirikizumab, Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 37
States / cities: Dothan, Alabama • Anaheim, California • Beverly Hills, California + 30 more

Conditions: Asthma
Interventions: Fp/ABS, FP, ABS, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 12 Years and older
Enrollment: 649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 91
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 73 more

Conditions: Crohn's Disease
Interventions: Guselkumab, Golimumab, JNJ-78934804, Placebo; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 703 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 90
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 79 more

Conditions: Obesity, Overweight and/or Obesity, Knee Osteoarthritis, Diabetes Melliuts, Type 2
Interventions: Berobenatide, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Birmingham, Alabama • Tucson, Arizona • Miami, Florida + 1 more

Conditions: Bone Marrow Failure Syndromes, Aplastic Anemias, Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Relapse, Severe Aplastic Anemia, Refractory, Non-severe Aplastic Anemia
Interventions: Dibotatug (DR-01); Drug
Lead sponsor: Dren Bio; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 10
States / cities: Duarte, California • Palo Alto, California • Miami, Florida + 7 more

Conditions: Non-infected Venous Leg Ulcer, Venous Leg Ulcer, Venous Insufficiency, Venous Stasis, Venous Reflux
Interventions: BR-AC, Standard Care; Other
Lead sponsor: BioStem Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 22
States / cities: Guntersville, Alabama • Castro Valley, California • Glendale, California + 16 more

Conditions: Colitis, Ulcerative
Interventions: Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 32
States / cities: Litchfield Park, Arizona • Apple Valley, California • Lancaster, California + 26 more

Conditions: Chronic Pain, Low Back Pain
Interventions: LY4065967, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Palm Springs, California + 30 more

Clinical trials in Miami, Florida

Filter and sort this location

Live official records

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes

Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain